Señales en vivo de 3759.HK | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 04:08):

Stats
Volumen de hoy	7.20M
Volumen promedio	5.09M
Capitalización de mercado	33.93B
EPS	HKD0.371 ( 2023-06-30 )
Last Dividend	HKD0.329 ( 2023-07-18 )
Next Dividend	HKD0 ( N/A )
P/E	11.58
ATR14	HKD0.0150 (0.14%)

Volumen Correlación

Largo: -0.02 (neutral)

Corto: -0.19 (neutral)

Signal:(50.114) Neutral

Pharmaron Beijing Co., Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pharmaron Beijing Co., Correlación - Moneda/Commodity

-0.21
( neutral )

-0.41
( neutral )

0.00
( neutral )

-0.30
( neutral )

0.44
( neutral )

0.42
( neutral )

Pharmaron Beijing Co., Finanzas

Annual	2023
Ingresos:	HKD11.54B
Beneficio Bruto:	HKD4.12B (35.75 %)
EPS:	HKD0.900

FY	2023
Ingresos:	HKD11.54B
Beneficio Bruto:	HKD4.12B (35.75 %)
EPS:	HKD0.900

FY	2022
Ingresos:	HKD10.27B
Beneficio Bruto:	HKD3.77B (36.71 %)
EPS:	HKD1.160

FY	2021
Ingresos:	HKD7.44B
Beneficio Bruto:	HKD2.68B (35.99 %)
EPS:	HKD2.10

Financial Reports:

No articles found.

Pharmaron Beijing Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.329 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Pharmaron Beijing Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.01 - Stable (20.26%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.109	2020-06-01
Last Dividend	HKD0.329	2023-07-18
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	4	--
Total Paid Out	HKD1.208	--
Avg. Dividend % Per Year	0.00%	--
Score	3.16	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.01
Div. Directional Score	8.72	--

Next Divdend (Est)
(2024-07-19)

HKD0.220 Estimate 3.08 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.16

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6868.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
1970.HK	Ex Dividend Knight	2023-06-09	Semi-Annually	0.00%
0995.HK	Ex Dividend Knight	2023-06-13	Annually	0.00%
0101.HK	Ex Dividend Junior	2023-09-12	Semi-Annually	0.00%
3347.HK	Ex Dividend Junior	2023-05-25	Annually	0.00%
1571.HK	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
0598.HK	Ex Dividend Junior	2023-09-08	Annually	0.00%
9908.HK	Ex Dividend Junior	2023-09-18	Annually	0.00%
2148.HK	Ex Dividend Junior	2023-10-03	Sporadic	0.00%
1133.HK	Ex Dividend Junior	2023-06-15	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.129	1.500	7.42	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0588	1.200	8.04	9.65	[0 - 0.3]
returnOnEquityTTM	0.122	1.500	9.76	10.00	[0.1 - 1]
payoutRatioTTM	0.321	-1.000	6.79	-6.79	[0 - 1]
currentRatioTTM	2.52	0.800	2.42	1.938	[1 - 3]
quickRatioTTM	2.06	0.800	2.62	2.09	[0.8 - 2.5]
cashRatioTTM	1.234	1.500	4.26	6.39	[0.2 - 2]
debtRatioTTM	0.327	-1.500	4.55	-6.83	[0 - 0.6]
interestCoverageTTM	8.18	1.000	8.08	8.08	[3 - 30]
operatingCashFlowPerShareTTM	1.674	2.00	9.44	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.220	2.00	9.89	10.00	[0 - 20]
debtEquityRatioTTM	0.650	-1.500	7.40	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.350	1.000	7.50	7.50	[0.2 - 0.8]
operatingProfitMarginTTM	0.147	1.000	9.07	9.07	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.360	1.000	9.11	9.11	[0.2 - 2]
assetTurnoverTTM	0.455	0.800	-0.300	-0.240	[0.5 - 2]
Total Score				11.43

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.49	1.000	8.94	0	[1 - 100]
returnOnEquityTTM	0.122	2.50	9.84	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.220	2.00	9.93	10.00	[0 - 30]
dividendYielPercentageTTM	3.71	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.674	2.00	9.44	10.00	[0 - 30]
payoutRatioTTM	0.321	1.500	6.79	-6.79	[0 - 1]
pegRatioTTM	0.0153	1.500	-3.23	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.259	1.000	6.04	0	[0.1 - 0.5]
Total Score				6.01

Pharmaron Beijing Co.,

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.